Author Interviews, JAMA, Schizophrenia / 26.07.2016
Adjuvant Raloxifene Treatment Promising For Women With Refractory Schizophrenia
MedicalResearch.com Interview with:
[caption id="attachment_26441" align="alignleft" width="133"]
Prof. Jayashri Kulkarni[/caption]
Professor Jayashri Kulkarni MBBS, MPM,
FRANZCP, PhD
Director, Monash Alfred Psychiatry research centre
Vic Australia
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Schizophrenia is a complex psychiatric disorder and many patients are not able to achieve remission on the available treatments. There are clear sex differences in many aspects of the illness, which not only implicates a role for the sex hormone estrogen in schizophrenia, but also highlights the need for sex-specific treatments.
Our group has conducted many clinical trials using adjunctive estradiol treatment, with excellent improvement in psychotic symptoms- however, there can be physical side effects with longer term estradiol use. Raloxifene and other selective estrogen receptor modulators ( SERMs) - the so-called "brain estrogens", with their more specific brain impacts and less body side effects - provide an option to use longer term estrogen in people with refractory schizophrenia. We conducted the first ever pilot study of raloxifene in 2010, and now present findings from a bigger study of adjunctive raloxifene treatment in schizophrenia.
Prof. Jayashri Kulkarni[/caption]
Professor Jayashri Kulkarni MBBS, MPM,
FRANZCP, PhD
Director, Monash Alfred Psychiatry research centre
Vic Australia
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Schizophrenia is a complex psychiatric disorder and many patients are not able to achieve remission on the available treatments. There are clear sex differences in many aspects of the illness, which not only implicates a role for the sex hormone estrogen in schizophrenia, but also highlights the need for sex-specific treatments.
Our group has conducted many clinical trials using adjunctive estradiol treatment, with excellent improvement in psychotic symptoms- however, there can be physical side effects with longer term estradiol use. Raloxifene and other selective estrogen receptor modulators ( SERMs) - the so-called "brain estrogens", with their more specific brain impacts and less body side effects - provide an option to use longer term estrogen in people with refractory schizophrenia. We conducted the first ever pilot study of raloxifene in 2010, and now present findings from a bigger study of adjunctive raloxifene treatment in schizophrenia.




















